HUTCHMED to Unveil Data at ASCO 2026 Annual Meeting

Stock News05-22

HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.

Results from the pivotal Phase II registration study in China of savolitinib for the treatment of patients with gastric or gastroesophageal junction adenocarcinoma harboring MET amplification will be featured in a rapid oral abstract session. The study met its primary endpoint of objective response rate (ORR) as assessed by an Independent Review Committee (IRC) per RECIST 1.1 criteria. As of the data cutoff date of October 8, 2025, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included an IRC-assessed disease control rate (DCR) of 63.1%, a median time to response (TTR) of 1.4 months, a median duration of response (DoR) of 9.7 months (95% CI: 3.7, 18.5), and a median progression-free survival (PFS) of 4.0 months (95% CI: 2.6, 5.0). These data supported the submission of a New Drug Application to China's National Medical Products Administration, which was accepted and granted priority review in December 2025.

Furthermore, additional analyses from the FRESCO, FRESCO-2, FRUSICA-1, and FRUSICA-2 studies of fruquintinib, along with results from investigator-initiated trials of fruquintinib and surufatinib in multiple potential oncology indications, will also be presented at the conference.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148854714?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148854714","market":"fut","top_or_hot":-1,"title":"HUTCHMED to Unveil Data at ASCO 2026 Annual Meeting","media":"Stock News","content":"<p>HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.</p>\n<p>Results from the pivotal Phase II registration study in China of savolitinib for the treatment of patients with gastric or gastroesophageal junction adenocarcinoma harboring MET amplification will be featured in a rapid oral abstract session. The study met its primary endpoint of objective response rate (ORR) as assessed by an Independent Review Committee (IRC) per RECIST 1.1 criteria. As of the data cutoff date of October 8, 2025, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included an IRC-assessed disease control rate (DCR) of 63.1%, a median time to response (TTR) of 1.4 months, a median duration of response (DoR) of 9.7 months (95% CI: 3.7, 18.5), and a median progression-free survival (PFS) of 4.0 months (95% CI: 2.6, 5.0). These data supported the submission of a New Drug Application to China's National Medical Products Administration, which was accepted and granted priority review in December 2025.</p>\n<p>Furthermore, additional analyses from the FRESCO, FRESCO-2, FRUSICA-1, and FRUSICA-2 studies of fruquintinib, along with results from investigator-initiated trials of fruquintinib and surufatinib in multiple potential oncology indications, will also be presented at the conference.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED to Unveil Data at ASCO 2026 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED to Unveil Data at ASCO 2026 Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-22 08:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.</p>\n<p>Results from the pivotal Phase II registration study in China of savolitinib for the treatment of patients with gastric or gastroesophageal junction adenocarcinoma harboring MET amplification will be featured in a rapid oral abstract session. The study met its primary endpoint of objective response rate (ORR) as assessed by an Independent Review Committee (IRC) per RECIST 1.1 criteria. As of the data cutoff date of October 8, 2025, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included an IRC-assessed disease control rate (DCR) of 63.1%, a median time to response (TTR) of 1.4 months, a median duration of response (DoR) of 9.7 months (95% CI: 3.7, 18.5), and a median progression-free survival (PFS) of 4.0 months (95% CI: 2.6, 5.0). These data supported the submission of a New Drug Application to China's National Medical Products Administration, which was accepted and granted priority review in December 2025.</p>\n<p>Furthermore, additional analyses from the FRESCO, FRESCO-2, FRUSICA-1, and FRUSICA-2 studies of fruquintinib, along with results from investigator-initiated trials of fruquintinib and surufatinib in multiple potential oncology indications, will also be presented at the conference.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"","article_id":"1148854714","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148854714","pubTimestamp":1779409463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念","BK1587":"次新股","BK4007":"制药","HCM":"和黄医药","BK4531":"中概回港概念","00013":"和黄医药"},"translate_title":"和黄医药将在ASCO 2026年年会上公布数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) has announced that the latest and updated data from several studies of its self-developed compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29 to June 2, 2026, in Chicago, USA.\nResults from the pivotal Phase II registration study in China of savolitinib for the treatment of patients with gastric or gastroesophageal junction adenocarcinoma harboring MET amplification will be featured in a rapid oral abstract session. The study met its primary endpoint of objective response rate (ORR) as assessed by an Independent Review Committee (IRC) per RECIST 1.1 criteria. As of the data cutoff date of October 8, 2025, the IRC-assessed ORR was 32.3% (95% CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included an IRC-assessed disease control rate (DCR) of 63.1%, a median time to response (TTR) of 1.4 months, a median duration of response (DoR) of 9.7 months (95% CI: 3.7, 18.5), and a median progression-free survival (PFS) of 4.0 months (95% CI: 2.6, 5.0). These data supported the submission of a New Drug Application to China's National Medical Products Administration, which was accepted and granted priority review in December 2025.\nFurthermore, additional analyses from the FRESCO, FRESCO-2, FRUSICA-1, and FRUSICA-2 studies of fruquintinib, along with results from investigator-initiated trials of fruquintinib and surufatinib in multiple potential oncology indications, will also be presented at the conference.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148854714","isCrawlerRequest":true}